ClinicalTrials.gg
CompletedNCT03680885Updated Jul 15, 2020

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

An Early Phase 1 interventional study of Lidocaine gel and Placebo in ADHD and Controls, sponsored by PhenoSolve, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-15.

Sponsored by PhenoSolve, LLC · Early Phase 1, Interventional, and Health services research

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
603rd of 706
20 · median 70
Started
2019
with 31 others
Phase 1
48 of 807
3 open now
Registered
548th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 603rd largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2019, is one of 48 in phase 1, and was the 548th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

This work will assess the reliability of a simple painless test for the effectiveness of the commonly used local anesthetic lidocaine

Read the detailed description

In prior tests with a convenience sample, subjects who reported that they had no trouble getting numb at the dentist, also got numb with lidocaine gel on the surface of the tongue. That numbness prevented them from being able to taste any flavor until the numbness had worn off. Subjects who reported having trouble getting numb at the dentist, could still taste flavors after the application of lidocaine.

This work will assess the reliability of a taste-based approach for creating a non-invasive way to test lidocaine effectiveness. The controlled trial will assess the ability of lidocaine oral gel to block taste (e.g., sweet) in 20 adults (ages 18-49) half with history of trouble getting numb at the dentist (Arm 2) and half with no trouble (Arm 1). To determine reproducibility, the taste-based test will be done 4 times on different days, twice with lidocaine and twice with a placebo, with randomization and double-blinding. These repeated results will be compared to a fifth assessment, against the "gold standard" of injection of lidocaine, assessed using a dental probe.

On each of four separate visits, in randomized order, the subject will be tested with tastants to the tongue twice after application of a lidocaine gel to the tongue and twice with a placebo gel. After a wait of two-minutes, the three tastants will be tested. The subject is blinded to the taste and the identity of the gel, which have been compounded to look the same.

On the fifth (last) visit, the subject will get an oral injection of lidocaine and the numbness assessed.

The results across the five tests will then be analyzed.

We are testing in separate studies NCT 03563573 and NCT 03676725 the prevalence of lidocaine ineffectiveness in those with Attention Deficit Hyperactivity Disorder (ADHD) and in the general population without ADHD. We believe the prevalence will be higher in ADHD. As a result, in this evaluation we have one Arm "gets numb at the dentist" where exclusion criteria includes ADHD and a second Arm "has trouble getting numb at the dentist" that does not have that exclusion.

03

Conditions studied

  • ADHD
  • Controls

Keywords

  • Lidocaine ineffectiveness
  • ADHD
  • ADD
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Arm 1 Eligibility

Inclusion Criteria:

  • Report "get numb at dentist"

Exclusion Criteria:

  • ADHD, ADD, and other inattention disorders
  • Known adverse reactions to lidocaine;
  • Epilepsy
  • IQ \<80
  • Severe head trauma
  • Birth weight \<2270 grams
  • Severe autism
  • Generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness)
  • Mouth sores
  • Ehlers Danlos syndrome
  • Red hair
  • Current pregnancy
  • Treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers

Angiotensin Converting Enzyme Inhibitors

  • Alacepril (not available in US)
  • Benazepril (Lotensin)
  • Captopril (trade name Capoten)
  • Cilazapril (Inhibace)
  • Delapril (not available in US)
  • Enalapril (Vasotec/Renitec)
  • Fosinopril (Fositen/Monopril)
  • Imidapril (Tanatril)
  • Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril)
  • Moexipril (Univasc)
  • Perindopril (Coversyl/Aceon/Perindo)
  • Quinapril (Accupril)
  • Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace)
  • Spirapril (Renormax)
  • Temocapril (not available in US)
  • Teprotide (but not active by oral administration and not used in US)
  • Trandolapril (Mavik/Odrik/Gopten)
  • Zofenopril

Angiotensin receptor blockers

  • Azilsartan (Edarbi)
  • Candesartan (Atacand)
  • Eprosartan (Teveten)
  • Fimasartan (Kanarb)
  • Irbesartan (Avapro)
  • Losartan (Cozaar)
  • Olmesartan (Benicar/Olmetec)
  • Telmisartan (Micardis)
  • Valsartan (Diovan)

Aldosterone antagonists

  • Spironolactone (Aldactone)
  • Eplerenone (Inspra)

Renin inhibitors - Aliskiren (Tekturna, Rasilez)

Other potassium elevating agents

  • Antibiotics, including penicillin G and trimethoprim
  • Azole antifungals
  • Beta-blockers
  • Herbal supplements, including milkweed, lily of the valley, Siberian ginseng, Hawthorn berries
  • Heparin
  • Nonsteroidal anti-inflammatory medications (NSAIDs)
  • Oral containing drospirenone

Arm 2 Eligibility

Inclusion Criteria:

  • Report "trouble getting numb at dentist"

Exclusion Criteria:

  • Known adverse reactions to lidocaine;
  • Epilepsy
  • IQ \<80
  • Severe head trauma
  • Birth weight \<2270 grams
  • Severe autism
  • Generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness)
  • Mouth sores
  • Ehlers Danlos syndrome
  • Red hair
  • Current pregnancy
  • Treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers

Angiotensin Converting Enzyme Inhibitors

  • Alacepril (not available in US)
  • Benazepril (Lotensin)
  • Captopril (trade name Capoten)
  • Cilazapril (Inhibace)
  • Delapril (not available in US)
  • Enalapril (Vasotec/Renitec)
  • Fosinopril (Fositen/Monopril)
  • Imidapril (Tanatril)
  • Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril)
  • Moexipril (Univasc)
  • Perindopril (Coversyl/Aceon/Perindo)
  • Quinapril (Accupril)
  • Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace)
  • Spirapril (Renormax)
  • Temocapril (not available in US)
  • Teprotide (but not active by oral administration and not used in US)
  • Trandolapril (Mavik/Odrik/Gopten)
  • Zofenopril

Angiotensin receptor blockers

  • Azilsartan (Edarbi)
  • Candesartan (Atacand)
  • Eprosartan (Teveten)
  • Fimasartan (Kanarb)
  • Irbesartan (Avapro)
  • Losartan (Cozaar)
  • Olmesartan (Benicar/Olmetec)
  • Telmisartan (Micardis)
  • Valsartan (Diovan)

Aldosterone antagonists

  • Spironolactone (Aldactone)
  • Eplerenone (Inspra)

Renin inhibitors

  • Aliskiren (Tekturna, Rasilez)

Other potassium elevating agents

  • Antibiotics, including penicillin G and trimethoprim
  • Azole antifungals
  • Beta-blockers
  • Herbal supplements, including milkweed, lily of the valley, Siberian ginseng, Hawthorn berries
  • Heparin
  • Nonsteroidal anti-inflammatory medications (NSAIDs)
  • Oral contraceptives containing drospirenone
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Reports getting numb at dentist

    Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.

    Drug: Lidocaine gel · Drug: Placebo · Drug: Injected lidocaine

  • Active comparator
    Reports trouble getting numb at dentist

    Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.

    Drug: Lidocaine gel · Drug: Placebo · Drug: Injected lidocaine

Interventions

  • Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)

    Also known as: Intervention

  • DrugPlacebo

    PEG with FD\&C Blue No.1 (Brilliant Blue FCF)

    Also known as: Control gel

  • DrugInjected lidocaine

    Standard FDA-approved dental injectable lidocaine

    Also known as: Current practice

06

What researchers measure

Primary outcomes

  1. Taste sensation after lidocaine or placebo

    The subject is blinded to the tastant and gel identities. The 3 tastants are tested in randomized order. After application of lidocaine gel or placebo to the tongue, and a wait of 2 minutes, the subject's tongue is rubbed with a swab that has been wet with the tastant on the subject's tongue. The subject is asked to identify the taste (e.g., sweet). Then, on a 5-point scale (0-4, ranging from none to very intense) they are asked to rate the intensity of the taste. The process is repeated for each of the three tastants. The consistency of the subject responses over the 4 sessions will be analyzed.

    Time frame: 4 visits each of 30 minutes within weeks of one another, average ~1 month total

  2. Ability to feel pressure and discomfort after injection of lidocaine into the cheek

    Inject lidocaine as would be done in a dental visit, assess numbness to pressure and discomfort using the Baker Wong FACES scale (0-10) scale of discomfort, ranging from none to intense pain. The effectiveness of lidocaine will be assessed, and then the results compared to Outcome 1.

    Time frame: 1 visit of 30 minutes after other 4 visits, average ~1 month total

07

Study locations

1 site
  • Jacobi Medical Center
    Bronx, New York 10461, United States
08

References and documents

Publications

  • Infante MA, Moore EM, Nguyen TT, Fourligas N, Mattson SN, Riley EP. Objective assessment of ADHD core symptoms in children with heavy prenatal alcohol exposure. Physiol Behav. 2015 Sep 1;148:45-50. doi: 10.1016/j.physbeh.2014.10.014. Epub 2014 Oct 23. PubMed 25447751 ↗
  • Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. 2008 Apr 21;6:18. doi: 10.1186/1479-5876-6-18. Erratum In: J Transl Med. 2014;12:198. Dosage error in article text. PubMed 18426576 ↗
  • Nakai Y, Milgrom P, Mancl L, Coldwell SE, Domoto PK, Ramsay DS. Effectiveness of local anesthesia in pediatric dental practice. J Am Dent Assoc. 2000 Dec;131(12):1699-705. doi: 10.14219/jada.archive.2000.0115. PubMed 11143733 ↗
  • Segal MM. We cannot say whether attention deficit hyperactivity disorder exists, but we can find its molecular mechanisms. Pediatr Neurol. 2014 Jul;51(1):15-6. doi: 10.1016/j.pediatrneurol.2014.04.014. Epub 2014 Apr 18. No abstract available. PubMed 24938135 ↗
  • Segal MM, Rogers GF, Needleman HL, Chapman CA. Hypokalemic sensory overstimulation. J Child Neurol. 2007 Dec;22(12):1408-10. doi: 10.1177/0883073807307095. PubMed 18174562 ↗
  • Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol. 1997 Jun;77(6):3021-34. doi: 10.1152/jn.1997.77.6.3021. PubMed 9212254 ↗
  • Teicher MH, Polcari A, Fourligas N, Vitaliano G, Navalta CP. Hyperactivity persists in male and female adults with ADHD and remains a highly discriminative feature of the disorder: a case-control study. BMC Psychiatry. 2012 Nov 7;12:190. doi: 10.1186/1471-244X-12-190. PubMed 23134619 ↗
  • Mintz M, Badner V, Feldman LK, Mintz P, Saraghi M, Diaz J, Mezhebovsky I, Axelrod I, Gleeson J, Liu C, Smith C, Chow H, Zurakowski D, Segal MM. Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target. Psychopharmacol Bull. 2022 Jun 27;52(3):20-30. PubMed 35815177 ↗

Individual participant data

Plan to share: Yes — We plan to share with the FDA the validation of the taste approach to testing lidocaine effectiveness, as part of an IDE application.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 9-12 months

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Mar 2020, 7 months.

Of 21 industry-sponsored phase 1 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 2 months of starting (the median); a quarter within 1 and three quarters within 7. This study's 7 months is above that.

Counting every sponsor, half of 35 studies reached it within 9 months; a quarter within 2 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Sep 21, 2018
StartActual
Aug 1, 2019
Primary completionActual
Mar 30, 2020
CompletionActual
Mar 30, 2020
Last update
Jul 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03680885
Lead sponsor
PhenoSolve, LLC
Collaborators
Jacobi Medical Center
Responsible party
Sponsor
First posted
Sep 21, 2018
Start date
Aug 1, 2019
Primary completion
Mar 30, 2020
Completion
Mar 30, 2020
Last update
Jul 15, 2020

Study contacts

Michael Segal, MD PhD
principal investigator · PhenoSolve, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion